AffaMed and VistaGen Start China Phase III Trial of Social Anxiety Therapy
publication date: Apr 12, 2022
Shanghai AffaMed and VistaGen, a South San Francisco company, have filed an IND to conduct a China Phase III trial of their partnered therapy for adults with acute social anxiety disorder (SAD). PH94B is an odorless, as-needed, fast-acting (15 minutes) neuroactive pherine nasal spray with a novel mechanism of action. PALISADE Global is designed to evaluate the efficacy, safety and tolerability of VistaGen’s PH94B in China and other ex-US markets. The two companies plan to expand the Phase III trial into Canada, Mexico and South Korea. More details....
Stock Symbol: (NSDQ: VTGN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.